BeStock  
Stocks › Biotechnology › URGN

UroGen Pharma Ltd URGN

US equityMarket cap rank #2953Biotechnology
$27.65 −$4.08 (-12.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.65 0.00%
Open$31.15
Prev close$31.73
Day range$27.57 – $31.90
Volume2.40M
Market cap$1.36B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership101.9%+2.35 pts vs. prior quarter
Institutions holding246+16 vs. prior quarter
Insider trades (recent)31 buys / 19 sellsNet buying
Short interest10.45% of floatDays to cover 5.1 · as of 30 Oct 2026
Short-sale volume share19.0%5-day average of daily volume

Short-sale volume as % of daily volume

6%14%23%31%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$1.91M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

+$923.7KSuper+$990.1KBig+$987.6KMid+$1.6MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 31.8% of shares outstanding.

Largest holders

  • RTW Investments, LP9.26%
  • The Toronto-Dominion Bank6.87%
  • BlackRock6.24%
  • Kynam Capital Management, LP4.96%
  • Jefferies Financial Group Inc.4.48%
  • Morgan Stanley4.43%
  • Morgan Stanley Investment Management Inc.4.43%
  • SG Americas Securities, LLC4.19%

By investor type

  • Mutual Fund36.10%
  • Hedge Fund31.83%
  • Public Company19.06%
  • VC/PE Fund9.15%
  • Private Company4.40%
  • Individual/Insider1.89%
  • Government Pension Fund1.07%
  • Insurance Company0.21%

Reported short interest has held roughly steady near 10.45% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Federated Hermes, Inc. Mutual Fund 2026/Q3 +304,259 0.6%
JPMorgan Chase & Co. Public Company 2026/Q3 +171,257 0.4%
UBS Asset Management Mutual Fund 2026/Q3 +144,757 0.5%
Squarepoint OPS LLC Hedge Fund 2026/Q3 +105,500 0.2%
Russell Investment Management, LLC Mutual Fund 2026/Q3 +88,097 0.4%
Raymond James Financial, Inc. Public Company 2026/Q3 +60,148 0.1%
Robert L. Bender, Inc. Mutual Fund 2026/Q3 +34,701 0.1%
BNP Paribas Financial Markets SNC Private Company 2026/Q3 +34,049 0.2%
FMR Mutual Fund 2026/Q3 +33,804 0.5%
Calamos Investments LLC Mutual Fund 2026/Q3 +97,953 0.2%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +87,557 0.2%
Point72 Asset Management, L.P. Hedge Fund 2026/Q3 +1,525,549 3.1%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q3 +1,065,939 2.2%
The Toronto-Dominion Bank Public Company 2026/Q3 +753,243 6.9%
SG Americas Securities, LLC Private Company 2026/Q3 +395,060 4.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
7 Oct 2026 Christopher Degnan Chief Financial Officer Derivative Exercise and Sale -2,202 $36.69 4,561
7 Oct 2026 Christopher Degnan Chief Financial Officer Derivative Exercise and Retained +2,281 – 4,561
7 Sep 2026 Mark Schoenberg Chief Medical Officer Intent to Sell (Form 144) -871 $44.09 –
7 Sep 2026 Jason Smith General Counsel, Chief Compliance Officer & Corporate Secretary Intent to Sell (Form 144) -1,519 $44.09 –
7 Sep 2026 Mark Schoenberg Chief Medical Officer Derivative Exercise and Sale -871 $42.92 59,882
7 Sep 2026 Jason Smith General Counsel, Chief Compliance Officer & Corporate Secretary Derivative Exercise and Sale -1,519 $42.54 53,141
6 Sep 2026 Mark Schoenberg Chief Medical Officer Derivative Exercise and Retained +796 – 59,882
6 Sep 2026 Jason Smith General Counsel, Chief Compliance Officer & Corporate Secretary Derivative Exercise and Retained +1,815 – 53,141
25 Aug 2026 James Robinson Independent Director Derivative Exercise and Retained +2,000 – 8,000
19 Aug 2026 Mark Schoenberg Chief Medical Officer Open Market Disposition -60,677 $47.05 59,086
8 Jul 2026 Mark Schoenberg Chief Medical Officer Automatic Disposition -10,000 $40.00 119,763
21 Jun 2026 Cynthia Butitta Independent Director Other Derivative Acquisition +8,000 – 8,000
21 Jun 2026 Cynthia Butitta Independent Director Other Derivative Acquisition +10,000 $34.99 10,000
21 Jun 2026 Stuart Holden Independent Director Other Derivative Acquisition +20,000 $34.99 20,000
21 Jun 2026 Arie Belldegrun Independent Chairperson Other Derivative Acquisition +20,000 $34.99 20,000
21 Jun 2026 Daniel Wildman Independent Director Other Derivative Acquisition +8,000 – 8,000
21 Jun 2026 Daniel Wildman Independent Director Other Derivative Acquisition +10,000 $34.99 10,000
21 Jun 2026 Mark Schoenberg Chief Medical Officer Automatic Disposition -10,000 $35.01 129,763
21 Jun 2026 James Robinson Independent Director Other Derivative Acquisition +8,000 – 8,000
21 Jun 2026 James Robinson Independent Director Other Derivative Acquisition +10,000 $34.99 10,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 5,107,819 10.4% 5.1
15 Oct 2026 5,607,261 11.5% 4.9
30 Sep 2026 7,766,918 15.9% 9.9
15 Sep 2026 6,247,498 12.8% 9.2
31 Aug 2026 6,245,387 12.8% 6.8
14 Aug 2026 5,120,407 10.5% 4.8

Discussion

No comments yet — be the first to weigh in on URGN.

Sign in to join the discussion.

Scroll to Top